Mr. Ignelzi currently serves as the Chief Financial Officer at Rapport Therapeutics, Inc., a precision neuromedicines company, where he has served since November 2023. Prior to that, he was Chief Financial Officer at Karuna Therapeutics, Inc., a neurological disease company, (acquired by Bristol Myers Squibb), where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at Juventas Therapeutics and scPharmaceuticals. Mr. Ignelzi began his career at Eli Lilly, and then held roles of increasing responsibility at several biotechnology companies including Esperion Therapeutics, Inc. and Insys Therapeutics, Inc. Previously, Mr. Ignelzi served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023. He currently serves on the boards of Vedanta Biosciences and Abivax and is an Executive Advisor for Sofinnova Investments. Mr. Ignelzi is a graduate of Ferris State University, where he earned his B.S. in accounting.
« Go Back
